NK activity against the K562 target cell increased in most patients during the first week of treatment and then returned to below or near pretreatment levels thereafter against the K562 target cell. This contrasted with NK activity against the melanoma target cell which showed a more gradual increase over the duration of the treatment in 6 patients. The latter correlated with an increase in mitogen stimulated IL 2 production from their blood lymphocytes and may indicate that the cytotoxic activity resulted from lymphokine-activated killer (LAK) cells.
Systemic therapy for patients with unresectable metastatic melanoma is extremely poor and a variety of reignens have not altered the median survivals of the disease (Amer et al., 1979; Feun et al., 1982) . Recent Phase I and II studies with leukocyte interferon (IFN-a) suggested that IFN-a from whole cells had activity against melanomas in a small proportion of patients (Krown et al., 1981) . Similar limited responses were also seen in patients treated with lymphoblastoid IFN (Retsas et al., 1983) . The amount of IFN from these sources was limited and it has only been with the advent of recombinant DNA technology that sufficient quantities of purified IFNs have been available for clinical studies over a wide range of dosages and *Present address: P. Hersey (Gutterman et al., 1982) .
In studies on patients with a variety of malignancies, objective responses were mainly seen in patients with lymphoma . Evaluation of these products in patients with melanoma is as yet, at an early stage. In a preliminary study IFN-a2 was given i.v. to 16 patients with disseminated melanoma using various dose regimes. Two patients had complete remissions and 5 had stabilization of their disease (Ernstoff et al., 1983) . Similar response rates were reported for rIFN-aA (Creagan, 1983 (Creagan, , 1984a .
The purpose of the present study was to further evaluate the therapeutic efficacy of rIFN-aA given in high doses i.m. in patients with metastatic ©) The Macmillan Press Ltd., 1985 melanoma and to monitor a variety of immune responses to determine whether these may assist in optimizing treatment in subsequent studies.
Materials and methods
Patients studied These were 15 patients attending the Sydney Melanoma Unit and 5 patients attending the Newcastle Melanoma Unit, with metastases from melanoma. A summary of their clinical details is given in Table I . Twelve were in good physical condition with a performance status of 0-1 assessed on a 5 point scale (Miller et al., 1981) Vital signs were recorded before each injection and hourly for 4-6h post injection. All patients were followed up by physical examination at two weekly intervals. Peripheral blood cell counts were repeated prior to each injection, in the first week then each week for 6 weeks and each 2 weeks thereafter. Blood chemistry was repeated once a week for 6 weeks then each 4 weeks. Chest X-ray and urinalysis was repeated each 4 weeks. Tumour status was reassessed at least once a month by tests pertinent to each patient. Treatment was discontinued if severe toxicity (Miller et al., 1981) and/or tumour progression became apparent. (Hersey et al., 1980 (Hersey et al., , 1981 . Blood monoculear cells (3 x 105, 105, and 3 x IO' in 0.5 ml) were incubated with 3 x I03 51Cr-labelled MM200 or 104 K562 cells (in 0.5 ml) in overnight 16h assays in duplicate round bottomed tubes. Supernatants (0.5 ml) were harvested after centrifugation at 5OOg 7 min and counted. Percentage (Suzuki et al.,, 1983 ). In brief, supernatant (100lul) was added in doubling dilutions to triplicate cells with 2xl04 NK-7 cells for 18h and pulsed with lCi 125IUDR for 6h. A unit of IL2 was defined as the reciprocal dilution that induced 50% of the maximum IUDR uptake of a standard IL 2 preparation included in each assay. To reduce variability, supernatants from IL 2 production assays as above from each patient, were stored until the treatment with interferom was complete and all supernatants assayed at once against the NK-7 cells.
Statistical analysis
The complete remission rate and 95% confidence limits were obtained from the binomial distribution tables. Sequential changes in leukocyte populations were tested for significance by analysis of one way variance using data collected on days 1, 3, 10 and 31 using the "minitab" statistical package. Median survival was estimated from life tables constructed as described by Kaplan & Meier (1958) Melanoma Unit 6 h after administration of rIFNaxA are summarized in Table II . The total leukocyte count at 6 h post injection was unchanged at the 15 and 30 Mu m -2 dose but there was a marked reduction in lymphocyte counts and a corresponding increase in neutrophils. The reduction in lymphocyte count was attributed to a loss of T cells from the circulation which affected both T4 and T8 subpopulations. At the 50 Mum-2 dose there was a reduction in both neutrophils and lymphocytes. (There was a reciprocal increase in B cells at all dose levels.)
In contrast to the short term effects, longer term changes measured in blood samples taken prior to each administration of rIFN-aA, consisted of a reduction in total leukocyte counts which was due mainly to a reduction in neutrophils. Lymphocyte numbers were not markedly reduced and except for patients 3 did not exceed 50% of the pretreatment values. These results are shown in a summarized form in Table III as mean values before and during treatment. Analysis of T cell subsets by monoclonal antibodies revealed that the reduction of the OKT8 population tended to be greater than the T4 population giving an increase in the T4/T8 ratio in 10 of the patients. Exceptions to this were results from studies on patients 4, 6, 8, 12 and 15. These results are summarized in Figure 1 which indicates the change in mean lymphocyte counts whole on treatment in relation to changes in the T4/T8 ratio. The increase in T4/T8 ratio could not be accounted for by changes in lymphocyte counts. There was a significant decrease overall in B cell and monocyte (Figures 2a and 2b respectively.) NK activity returned to pretreatment or lower levels at day 7 or 9 of treatment and increases above pretreatment levels were seen only in patients 1, 4, 7, 8 and 9 after this period. In contrast NK activity increased in lymphocytes from 10 of the 14 patients against the MM200 target cells (Figure 3 ). Exceptions were patients 1, 3, 8 and 11. The increase was most prominent in those with low pretreatment values and tended to be more gradual than that noted against the K562 target cell. Increases in NK activity MM200 but not K562 were seen in studies on patients 4, 5, 6, 14 and 15.
Effects of rIFN-aeA on IL 2 production IL 2 production by blood lymphocytes taken at intervals during rIFN-aA administration is shown in Figure 4 . In 12 patients (No. 14 excepted) IL 2 production was less in samples taken during the first week of IFN treatment but recovered to or above pretreatment levels in the second or subsequent week or treatment. In 6 patients the changes in IL 2 production after the first week of treatment tended to parallel the changes in lymphocyte cytotoxicity against the MM200 target cell e.g. in studies on patient No. 1, 3, 6, 14 and 15. IL 2 production did not correlate with changes in the T4 or T8 T cell populations. Days of treatment with r IFN oA Figure 4 Sequential changes in IL 2 production from mitogen (PHA) stimulated PBL during treatment with rIFN-aA. In practically all patients there was an initial decrease in IL 2 production at 3rd day of treatment followed by a return to or above pretreatment levels. Mean + 1 s.d. of IL 2 production from 19 normal concurrent controls was 9.97 + 2.94 units.
Discussion
The response rate of melanoma to treatment by rIFN-aA in this study consisted of two complete remissions and stabilization of disease in two patients. One patient undergoing complete remission had a solitary pulmonary nodule and the other both pulmonary and s.c. nodules. Previous studies have also reported that responses to IFN-a were confined to metastases in skin (Retsas et al., 1983) or to skin and pulmonary regions (Creagan et al., 1984a,b; Pouillart et al., 1984) . It was noticeable that responses were confined to patients with a good performance status and there were no responses in those with restricted physical activity due to their disease. This contrasted with the study of Creagan et al., (1984b) who observed responses in both good and poor risk patients. Only one patient with extensive disease showed any response. This was a patient with extensive hepatic metastases which remained stable during treatment for a period of 8 months.
Evaluation of the patient with a bony metastases in the neck of the femur was difficult in that there appeared to be disease progression upon X-ray but there was no evidence of melanoma in scrapings obtained at operation for pin and plate of the hip. There was no evidence of tumour growth at this site over approximately a year so that this patient may have had a partial or complete response at this site. If this patient is included in the evaluation and the patient who only had 2 weeks of treatment is excluded the complete response rate was 3/19 patients or 16% (95% confidence levels 3.4-39.6%). If the patient is considered as unevaluable the complete response rate was 2/18 or 11% (95% confidence levels 1.4-34.77%). Median survival for all study participants from the beginning of treatment was 26 weeks by KaplanMeier life table analysis (Patient numbers are considered insufficient to make comparisons with published survivals of disseminated melanoma which is -6 months overall (Balch et al., 1985) .
As reported in other studies ) rIFN-axA administration was accompanied by a number of side effects which were severe enough to require dosage reduction from the 50Mum-2 dose in 11 of the 15 patients (see Appendix 1). This was usually from fatigue or a combination of fatigue and nausea. Severe hair loss was noticed in one patient after six months of treatment and grade three liver toxicity (Miller et al., 1981) was detected in two patients. Most patients were able to tolerate the 30 Mum-2 dose and this dose level or less would appear more realistic in future studies.
One of the objectives of the present study was to monitor effects of rIFN-xA on several haematological and immunological tests. Short term (6 h) effects on leukocyte populations consisted of a marked decrease in lymphocytes and an increase in neutrophils so that the total leukocyte numbers tended to remain unchanged. After the 50Mum-2 dose neutrophils did not increase, resulting in a decrease in total leukocyte numbers. The drop in lymphocyte numbers appeared to result from a reduction in T cells giving a relative increase in B cells. Lymphocyte numbers had returned towards pretreatment levels by two days prior to the next rIFN-axA injection so that the changes noted at 6h may have reflected sequestration of T cells from the circulation into sites such as the bone marrow. This is reported to occur after steroid administration (Haynes & Fauci, 1978) and in these patients may have resulted from endogenous steroid production as part of a stress response. The latter may also explain the marked reduction of NK activity in the circulation at 6h as steroids are known to produce this effect (Clarke et al., 1977; Holbrook et al., 1983) . Short term reduction in NK activity after rIFN-axA was also noted in previous studies (Lotzova et al., 1983) .
These short term effects on leukocyte populations appeared to be superimposed on a general depression of leukocyte numbers (particularly of neutrophils) and of platelets measured in blood samples taken before the next dose of rIFN-aA. The reduction in lymphocyte numbers was not marked and appeared to affect both B and T cells. The relative sparing of lymphocyte numbers in the blood was also noted in previous studies (Golub et al., 1982) and may indicate selective effects of rIFNaA on various progenitor cells in the marrow as reported elsewhere (Broxymeyer et al., 1983) . Within the T cell population there appeared to be a relative decrease in the T8 population, particularly when total lymphocyte numbers were reduced so that the T4/T8 ratio tended to increase. These changes are similar to those reported by Silver et al. (1983) using lymphoblastoid IFN and many reflect growth inhibitory effects of rIFN-a%A on T cell regeneration particularly if the T8 population has a higher turnover rate than the T4 population.
Short term changes in NK activity measured at 6h referred to above, appeared to be superimposed on longer term changes detected in blood samples taken 2 days after rIFN-aA administration. These were characterised, in general, by an increase against both target cells in the first week of administration. NK activity against the K562 target cells then declined to approximate pretreatment levels as described in previous studies using crude leukocyte interferon preparations (Golub et al., 1982) . As also noted in previous studies (Lotzova et al., 1983 ) the increase in NK activity was more marked in patients with low pretreatment values. Although the cytotoxic activity of blood lymphocytes against the two target cells was similar in the first week subsequent rIFN-axA treatment was associated (in 6 patients) with a gradual increase against the MM200 but not the K562 target cell. The latter changes did not correlate with changes in the T4 or T8 populations but did appear to correlate with IL 2 production from mitogen stimulated lymphocytes. These observations may indicate that the cytotoxic activity against the melanoma cell was due to lymphokine activated killer (LAK) cells. It was shown previously that the incubation of lymphocytes in IL 2 may induce cytotoxic activity against a wide range of target cells including autologous tumour cells (Hersey et al., 1981; Grimm et al., 1982) and are considered similar to the "anomalous killer cells" described by Masucci et al., (1980) . MM200 target cells are relatively resistant to NK activity but are sensitive to killing by LAK cells so that the increase in cytotoxic activity noted against the MM200 target cell but not the K562 cells may indicate endogenous production of LAK cells in response to enhanced IL 2 production. The latter may have been induced by administration of rIFNaA in the previous studies have shown potentiation of IL 2 production in vitro by IFN (Blomgren & Einhorn, 1981) .
The relevance of the results from the in vitro studies to the in vivo effects of rIFN-oaA on melanoma growth is at present uncertain. Although NK activity against K562 cells was increased in the first week of treatment this tended to be short lived in most of the patients. Previous studies have also raised doubt concerning the significance of NK activity in control of tumour growth in melanoma patients (Hersey et al., 1984) . (Belardelli et al., 1983 ) is unknown. With respect to future studies on rIFN-aA the response rate and complications observed in this study would not appear to justify further evaluation of dose regimes above 30Mum-2. This and other studies do however indicate the agent is effective against melanoma particularly in patients with a good performance status and pulmonary and or subcutaneous metastases. Further studies are required to select such patients who may respond to IFN and to develop optimal treatment regimes. The present studies suggest that measurement of IL2 production and LAK activity may assist in these aims. 
